Subtopic Deep Dive

Fluorine-Containing Pharmaceuticals
Research Guide

What is Fluorine-Containing Pharmaceuticals?

Fluorine-Containing Pharmaceuticals refers to clinically approved drugs and pipeline candidates incorporating fluorine atoms to enhance metabolic stability, potency, and pharmacokinetics.

This subtopic catalogs fluorinated drugs approved by FDA from 2016-2023, highlighting structural motifs like difluoromethyl and trifluoroethyl groups. Key reviews document over 20 new halogenated drugs in 2021 alone (Tiz et al., 2022). Fluorine substitution appears in therapeutics for oncology, infectious diseases, and neurology (Shabir et al., 2023).

15
Curated Papers
3
Key Challenges

Why It Matters

Fluorine boosts drug efficacy by blocking metabolic hotspots and improving membrane permeability, as seen in FDA-approved drugs like those reviewed by Shabir et al. (2023) spanning 2016-2022. In PET imaging, 18F-fluorination enables radiotracers for oncology diagnostics (Cole et al., 2014). Structural trends from these pharmaceuticals guide design of next-generation fluorodrugs, with applications in COVID-19 treatments (Chandra et al., 2023). Mei et al. (2019) show fluorinated amino acids enhance selectivity in drug design.

Key Research Challenges

Late-Stage Fluorination Scalability

Incorporating fluorine late in synthesis for pharmaceuticals faces low yields and catalyst incompatibility. Sap et al. (2021) review difluoromethylation methods using CF2H sources, but translation to GMP scale remains limited. PET radiotracer production struggles with rapid 18F decay (Cole et al., 2014).

Fluorine Metabolic Prediction

Predicting how fluorine alters drug metabolism and toxicity is imprecise despite stability gains. Shabir et al. (2023) note fluorine's role in pharmacokinetics, yet off-target effects persist. Riess and Blanc (1982) highlight perfluorochemical transport issues in biomedical applications.

Heterocyclic Fluorination Synthesis

Synthesizing fluorinated heterocycles for drugs requires regioselective methods. Rizzo et al. (2023) catalog FDA-approved fluorinated heterocycles from 2016-2022, but scalable routes are scarce. Kamlet et al. (2013) address palladium-mediated 18F-fluorination hurdles for PET translation.

Essential Papers

1.

Late-stage difluoromethylation: concepts, developments and perspective

Jeroen B. I. Sap, Claudio F. Meyer, Natan J. W. Straathof et al. · 2021 · Chemical Society Reviews · 366 citations

This review describes the conceptual advances that have led to the multiple difluoromethylation processes making use of well-defined CF<sub>2</sub>H sources.

2.

Solubility and transport phenomena in perfluorochemicals relevant to blood substitution and other biomedical applications

Jean G. Riess, Maurice Blanc · 1982 · Pure and Applied Chemistry · 283 citations

Abstract

3.

Applications of fluorine-containing amino acids for drug design

Haibo Mei, Jianlin Han, Karel D. Klika et al. · 2019 · European Journal of Medicinal Chemistry · 229 citations

4.

New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use

Davide Benedetto Tiz, Luana Bagnoli, Ornelio Rosati et al. · 2022 · Molecules · 144 citations

This review describes the recent Food and Drug Administration (FDA)-approved drugs (in the year 2021) containing at least one halogen atom (covalently bound). The structures proposed throughout thi...

5.

Radiosyntheses using Fluorine-18: The Art and Science of Late Stage Fluorination

Erin L. Cole, Megan N. Stewart, Ryan Littich et al. · 2014 · Current Topics in Medicinal Chemistry · 143 citations

Positron (β(+)) emission tomography (PET) is a powerful, noninvasive tool for the in vivo, three-dimensional imaging of physiological structures and biochemical pathways. The continued growth of PE...

6.

Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)

Ghulam Shabir, Aamer Saeed, Wajeeha Zahid et al. · 2023 · Pharmaceuticals · 107 citations

Fluorine is characterized by high electronegativity and small atomic size, which provide this molecule with the unique property of augmenting the potency, selectivity, metabolic stability, and phar...

7.

Application of Palladium-Mediated 18F-Fluorination to PET Radiotracer Development: Overcoming Hurdles to Translation

Adam S. Kamlet, Constanze N. Neumann, Eunsung Lee et al. · 2013 · PLoS ONE · 97 citations

New chemistry methods for the synthesis of radiolabeled small molecules have the potential to impact clinical positron emission tomography (PET) imaging, if they can be successfully translated. How...

Reading Guide

Foundational Papers

Start with Riess and Blanc (1982, 283 citations) for perfluorochemical basics in biomedicine, then Cole et al. (2014, 143 citations) for 18F radiosynthesis principles, and Kamlet et al. (2013, 97 citations) for PET translation challenges.

Recent Advances

Study Shabir et al. (2023, 107 citations) for 2016-2022 FDA fluorodrugs, Tiz et al. (2022, 144 citations) for 2021 approvals, and Rizzo et al. (2023, 75 citations) for fluorinated heterocycles.

Core Methods

Core techniques include difluoromethylation with CF2H sources (Sap et al., 2021), 18F late-stage fluorination (Cole et al., 2014), fluorinated amino acid incorporation (Mei et al., 2019), and palladium catalysis (Kamlet et al., 2013).

How PapersFlow Helps You Research Fluorine-Containing Pharmaceuticals

Discover & Search

Research Agent uses searchPapers and exaSearch to find FDA-approved fluorinated drugs, pulling 250M+ OpenAlex papers like Shabir et al. (2023) on 2016-2022 approvals. citationGraph reveals citation networks from foundational Riess and Blanc (1982) to recent Tiz et al. (2022), while findSimilarPapers uncovers related difluoromethylation reviews by Sap et al. (2021).

Analyze & Verify

Analysis Agent employs readPaperContent to extract synthesis routes from Cole et al. (2014) on 18F-fluorination, then verifyResponse with CoVe checks claims against 100+ similar papers. runPythonAnalysis with pandas/matplotlib quantifies fluorine trends in 50+ drug structures (e.g., citation counts vs. approval year), graded by GRADE for evidence strength in metabolic stability claims.

Synthesize & Write

Synthesis Agent detects gaps in late-stage fluorination for heterocycles, flagging contradictions between Sap et al. (2021) and Rizzo et al. (2023). Writing Agent uses latexEditText and latexSyncCitations to draft reviews citing Mei et al. (2019), with latexCompile generating polished PDFs and exportMermaid for drug motif diagrams.

Use Cases

"Extract fluorine positions and therapeutic areas from FDA-approved drugs 2016-2023"

Research Agent → searchPapers('FDA fluorinated drugs 2016-2023') → Analysis Agent → runPythonAnalysis(pandas parse 20 papers like Shabir et al. 2023) → CSV export of 50+ drugs with stats.

"Write LaTeX review on 18F-PET radiotracers in pharmaceuticals"

Research Agent → citationGraph(Cole et al. 2014) → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations(10 papers) + latexCompile → PDF with diagrams.

"Find GitHub repos with code for difluoromethylation simulations"

Research Agent → paperExtractUrls(Sap et al. 2021) → Code Discovery → paperFindGithubRepo + githubRepoInspect → Verified simulation scripts for drug design.

Automated Workflows

Deep Research workflow systematically reviews 50+ papers on fluorinated pharmaceuticals, chaining searchPapers → citationGraph → structured report on FDA trends (Shabir et al., 2023). DeepScan applies 7-step analysis with CoVe checkpoints to verify synthesis claims in Tiz et al. (2022). Theorizer generates hypotheses on fluorine motifs from Mei et al. (2019) and Rizzo et al. (2023) for novel drug scaffolds.

Frequently Asked Questions

What defines Fluorine-Containing Pharmaceuticals?

Clinically approved drugs and candidates with covalently bound fluorine enhancing potency and stability, as cataloged in Shabir et al. (2023) for 2016-2022 FDA approvals.

What are key synthesis methods?

Late-stage difluoromethylation (Sap et al., 2021), palladium-mediated 18F-fluorination (Kamlet et al., 2013), and trifluoroethylation of amines (Andrews et al., 2017).

What are landmark papers?

Shabir et al. (2023, 107 citations) on FDA-approved fluorodrugs 2016-2022; Tiz et al. (2022, 144 citations) on 2021 halogen drugs; foundational Riess and Blanc (1982, 283 citations) on perfluorochemicals.

What open problems exist?

Scalable late-stage fluorination for GMP (Sap et al., 2021), predicting fluorine toxicity, and regioselective heterocyclic fluorination (Rizzo et al., 2023).

Research Fluorine in Organic Chemistry with AI

PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:

Start Researching Fluorine-Containing Pharmaceuticals with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.